In a groundbreaking study spearheaded by researchers at the State University of Campinas (UNICAMP) in São Paulo, Brazil, a novel biomarker has been identified that could transform prognostic assessment for gastric cancer patients. Gastric cancer—ranked as the fifth most prevalent cancer worldwide—has long posed a challenge in predicting disease progression accurately. This innovative marker, derived from routine computed tomography (CT) imaging data, integrates complex measurements of visceral fat and muscle radiodensity to stratify patient risk more effectively than traditional tumor staging alone.

The multidisciplinary team, drawing expertise from both the Faculty of Medical Sciences (FCM) and the Gleb Wataghin Institute of Physics (IFGW) at UNICAMP, embarked on this research with backing from multiple grants awarded by the São Paulo Research Foundation (FAPESP). Their efforts culminated in the development of what they have termed the Visceral Muscle Difference (VMD) marker—a composite variable that captures metabolic and inflammatory properties of patient body composition using quantitative imaging parameters.

Conventionally, gastric cancer prognosis centers around tumor staging, an approach focusing primarily on the characteristics and spread of the tumor itself. However, this research introduces a paradigm shift by emphasizing the patient’s overall physiological state—not just the malignancy. The investigative team, including Professor José Barreto and co-advisor Jun Takahashi, advocates a holistic perspective that scrutinizes how body composition influences cancer outcomes, highlighting that tailored treatment must address the patient’s systemic condition to improve survival.

Central to the study was the analysis of data collected over a decade from 461 patients treated for gastric cancer at UNICAMP. Researchers meticulously analyzed their CT scans, quantifying radiodensity values of visceral adipose tissue and skeletal muscle. Radiodensity, an indicator of tissue’s capacity to attenuate X-rays during CT scanning, holds clues to underlying biological processes such as inflammation and metabolic health—factors increasingly recognized as critical modifiers of cancer progression.

By integrating these radiodensity values into a single metric, the VMD marker captures the complex interplay between fat and muscle tissue states in cancer patients. Intriguingly, the research reveals an inverse prognostic relationship: elevated radiodensity in adipose tissue correlates with poorer outcomes, possibly signalling inflammatory activation within the fat stores, while higher muscle radiodensity aligns with better survival rates, reflecting preserved muscle quality.

Quantitative analysis demonstrated striking survival disparities based on VMD scores. Patients with elevated VMD—a signifier of detrimental body composition—experienced a median survival of just 13.8 months, starkly contrasted with 58.5 months for those exhibiting healthier VMD profiles. This prognostic ability surpasses traditional staging, offering oncologists a powerful tool to identify high-risk patients who may require intensified or alternative therapeutic approaches.

The robustness of the VMD marker is further enhanced by its design, which strategically utilizes the difference between fat and muscle radiodensity rather than relying on absolute values for each tissue. This approach mitigates variability introduced by different CT scanner calibrations or technical inconsistencies, ensuring more reliable clinical implementation across diverse healthcare settings.

Harnessing advanced artificial intelligence techniques, the team employed machine learning algorithms to sift through the extensive imaging and clinical data. Unlike traditional univariate analyses, this methodology enabled rapid testing of multiple radiodensity combinations, refining the marker until it achieved optimal prognostic precision. “Teaching the machine to align with expert clinical insight while scaling data analysis exponentially was key,” explains Takahashi.

The implications of VMD extend beyond prognostication. Integrating this biomarker into clinical workflows could revolutionize treatment decision-making by unveiling the patient’s metabolic and inflammatory status—critical determinants often overlooked in standard cancer care. Personalized treatment regimens could emerge whereby aggressive chemotherapy is selectively administered to those with high-risk VMD profiles, whereas patients with favorable metrics might avoid unnecessary toxicity post-surgery, fundamentally improving quality of life.

Despite these promising findings, researchers caution that the study’s retrospective nature necessitates validation in prospective, multicenter cohorts encompassing broader demographics. Ensuring reproducibility across different populations and clinical environments is essential before VMD can be fully incorporated into routine practice. Moreover, the potential to modify a patient’s body composition profile therapeutically remains an open question, with ongoing investigations exploring whether nutritional or metabolic interventions can positively impact prognosis.

This study situates itself firmly within the evolving landscape of precision oncology, where understanding the host’s systemic biology complements tumor biology to refine cancer management. By leveraging data from standard CT scans—already integral to patient assessment—the VMD marker offers a cost-effective, readily accessible addition to the oncologist’s toolkit without imposing extra procedural burdens on patients.

Early exploratory studies initiated by the team suggest that the predictive value of the VMD marker may extend to other cancer types, potentially heralding a universal biomarker of cancer-related frailty and inflammation. As these lines of research mature, clinicians may soon navigate cancer treatment armed with unprecedented insights into the intricate interplay between tumor and host, tailoring therapeutics with unparalleled precision.

The diligent efforts of the UNICAMP team, supported by FAPESP, exemplify how interdisciplinary collaboration, cutting-edge technology, and patient-centered philosophy can converge to solve complex medical challenges. Their work opens a new chapter in gastric cancer prognosis, where the narrative shifts from focusing solely on the tumor mass to embracing the multifaceted biological portrait of the patient as a whole—paving the way for a future where personalized medicine is truly realized.

Subject of Research: Biomarker development for prognosis in gastric cancer utilizing CT scan-derived body composition radiodensity variables

Article Title: Determination of a new gastric cancer mortality predictor based on body composition radiodensity variables

News Publication Date: March 21, 2026

Web References:

• https://www.fapesp.br/en
• https://www.agencia.fapesp.br/en
• DOI: 10.1016/j.clnesp.2026.103132

References:

• Original article published in Clinical Nutrition ESPEN, 2026

Image Credits: FCM-UNICAMP

Keywords:
Gastric cancer, biomarker, prognosis, radiodensity, visceral fat, muscle, CT scan, body composition, machine learning, personalized medicine, inflammation, metabolic state

Digestive system cancers, encompassing malignancies of organs such as the esophagus, stomach, liver, pancreas, and colon, continue to represent a formidable challenge in global oncology due to their high incidence and mortality rates. Despite advancements in therapeutic modalities, prognostic uncertainties persist, complicating treatment strategies and patient counseling. Biomarkers that capture the complex interplay between inflammation, nutrition, and immunity are increasingly recognized for their capacity to refine prognosis predictions, yet the search for reliable, accessible, and integrative tools remains ongoing. The CALLY index emerges from this context, combining levels of C-reactive protein (CRP), albumin, and lymphocyte counts, effectively synthesizing critical biological domains linked to cancer progression.

The meta-analysis synthesized data from nineteen distinct studies involving nearly eight thousand patients, providing a robust statistical framework to evaluate the prognostic significance of the CALLY index across multiple survival endpoints. The researchers meticulously analyzed hazard ratios (HRs) for overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS), and cancer-specific survival (CSS). Each endpoint comprehensively reflects different facets of cancer prognosis—from general survival trends to relapse dynamics and mortality attributable directly to cancer.

One of the landmark findings was the consistent association between a lower CALLY index and poorer survival outcomes across all measured parameters. The pooled hazard ratio for overall survival nearly doubled for patients with a low CALLY score (HR = 1.973), highlighting a nearly twofold increased risk of mortality. Similarly, disease-free survival and recurrence-free survival exhibited significant adverse prognostic correlations with reduced CALLY index values. These robust associations were statistically significant, with p-values far below conventional thresholds, reinforcing the strength of the link.

Subgroup analyses further validated the clinical versatility and reliability of the CALLY index across heterogeneous patient populations and treatment modalities. Notably, the index retained strong predictive power regardless of the cancer subtype within the digestive system, treatment approach, threshold cutoff values used for classification, sample sizes, and even geographic variability. This level of consistency is paramount, suggesting the index’s potential universal applicability beyond localized cohorts or specific clinical settings.

Surgical patients, traditionally evaluated with a suite of clinical and pathological factors, demonstrated particularly pronounced predictive accuracy via the CALLY index. Here, the hazard ratio for overall survival was slightly above two, underpinning the possibility that preoperative evaluation of inflammatory and nutritional status provides invaluable prognostic insights. Such data could fundamentally enhance surgical candidacy decisions and postoperative management strategies.

Underlying the prognostic value of the CALLY index is its biological foundation. C-reactive protein is a well-established acute-phase reactant indicative of systemic inflammation, a hallmark of cancer progression and metastasis. Albumin reflects nutritional reserves and systemic health, which are critically linked to patient resilience and therapy tolerance. Lymphocyte counts serve as an immunological barometer, with depleted levels signifying impaired antitumor immunity. By combining these parameters, the CALLY index encapsulates a multidimensional snapshot of the host’s interaction with the cancer, integrating systemic inflammation, malnutrition, and immune competence.

This integrative approach advances beyond single biomarker assessments, addressing the complexity of tumor-host dynamics that drive disease trajectory. It aligns with the growing recognition in oncology that prognosis is not solely a function of tumor burden or molecular characteristics but is profoundly influenced by the patient’s systemic biological milieu. Consequently, the CALLY index represents both a paradigm shift and a practical tool, enabling clinicians to quantify this interplay effectively.

From a translational perspective, the cost-effectiveness and accessibility of the components—CRP, albumin, and lymphocyte counts routinely measured in clinical laboratories—position the CALLY index as a feasible addition to standard diagnostic workflows. Unlike expensive molecular assays or specialized imaging techniques, the index offers a scalable prognostic strategy suitable for diverse healthcare settings, including resource-limited environments.

The meta-analysis employed rigorous sensitivity analyses to ensure the robustness of their findings, mitigating concerns regarding study heterogeneity or publication bias. The minimal publication bias confirmed through statistical tests reinforces confidence in the reproducibility and generalizability of the conclusions drawn.

Clinical implications extend towards the potential integration of the CALLY index into multidisciplinary cancer care pathways. By identifying high-risk patients early, oncologists can tailor therapeutic regimens, prioritize nutritional and immunological interventions, and monitor inflammatory status more closely. This personalized approach could optimize both survival outcomes and quality of life.

Furthermore, the index may serve as a stratification factor in clinical trials, aiding in balanced cohort selection and more nuanced evaluation of investigational therapies. It also opens avenues for mechanistic research to explore the modulation of inflammation, nutrition, and immunity as therapeutic targets in digestive cancers.

As survival outcomes rely increasingly on individualized treatment paradigms, biomarkers such as the CALLY index promise to bridge gaps between laboratory science and bedside application. Their utility underscores a broader shift toward holistic patient assessment, recognizing that systemic biological context is as crucial as tumor-centric factors.

This study marks a significant milestone in oncological prognostication, advocating for the adoption of integrative indices over isolated markers. The evidence supports the wider clinical adoption of the CALLY index and underscores the imperative for further prospective studies and clinical trials to refine its predictive accuracy and therapeutic implications.

In summary, the CALLY index stands at the forefront of prognostic innovation, combining foundational biological insights with practical clinical application. Its demonstrated ability to predict survival outcomes in digestive system cancers reliably, consistently, and cost-effectively heralds a new era in cancer management—one that marries inflammation, nutrition, and immunity into a singular, actionable framework for improved patient care.

Subject of Research: Prognostic evaluation of the C-reactive protein-Albumin-Lymphocyte (CALLY) index in digestive system cancers

Article Title: Integrating inflammation, nutrition, and immunity: the CALLY index as a prognostic tool in digestive system cancers – a systematic review and meta-analysis

Article References:
Wu, B., Liu, J., Shao, C. et al. Integrating inflammation, nutrition, and immunity: the CALLY index as a prognostic tool in digestive system cancers – a systematic review and meta-analysis. BMC Cancer 25, 672 (2025). https://doi.org/10.1186/s12885-025-14074-3

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14074-3